Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma
Completed · Phase 1
Conditions studied: Thymic Carcinoma
In brief
This study is important to demonstrate if single agent activity is noted for patients with thymic tumors over expressing c-kit and/or PDGF. If this current trial is positive, it opens the door to evaluate other combination of drugs with imatinib in thymic tumors.
Key facts
- Study ID
- NCT00314873
- Run by
- Indiana University
- People needed
- 11
- Starts
- 2006-04-01
- Expected to finish
- 2011-03-01
- Last updated by the study team
- 2014-06-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histological or cytological proof of advanced C-KIT positive or PDGFR positive thymic carcinoma. For protocol purposes, advanced disease is defined as disease
- Patient must have at least one documented measurable lesion obtained by imaging within 28 days prior to being registered for protocol therapy.
- No prior imatinib therapy.
- Age > 18 years at the time of consent
- ECOG performance status of 0 or 1
- ANC ≥ 1500/mm3,Platelet count ≥ 100,000/mm,Total bilirubin < 1.5ULN,3.10 Serum creatinine ≤ 1.7 mg/dl,ALT and AST ≤ 3 x ULN
You may not qualify if…
- Clinically significant infections as judged by the treating investigator
- Clinically significant concurrent illnesses
- Females of childbearing potential not using birth control or breastfeeding
- Prior radiation therapy > 25% of the bone marrow
- Symptomatic brain metastasis
- History of Grade III/IV cardiac problems
- History of major surgery within 14 days prior to being registered
- Treatment with any investigational agent within 30 days prior to being registered for protocol therapy.
Where it is running
- Indiana University Cancer Center — Indianapolis, Indiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.